5–11 October 2026

◆◆◆◆◇  People, tested on a stand-in

Partial reprogramming reached first-in-human testing in three glaucoma patients

◆ Funding is not validationThe only account of this trial comes from the company that ran it.

Life Biosciences dosed three glaucoma patients with ER-100 in a first-in-human dose escalation, the first human data from a formal reprogramming trial. Earlier informal human use was never published. The company reported early visual-field improvement signals in two of the three patients. Two reports describe one trial, not two. In mice, a 16-day course of Yamanaka-factor induction reversed features of haematopoietic stem cell aging.

Three open-label patients with no serious adverse events so far do not establish tolerability, and the follow-up duration is unreported. A visual-field change in two people with no comparator is an observation, not an effect, and the company is the only source. ^1–4

HARMSNo serious adverse events to date in three patients; three people cannot make a safety profile. A separate unpublished report describes AAV-delivered partial reprogramming given informally outside trial structures. (none reported)

WHAT WOULD MOVE THISA controlled trial with prespecified visual-field endpoints, or a dataset published outside the company's own release.

1 Longevity.Technology · Phase I, first-in-human, single-arm dose escalation · n = 3  ·  2 STAT News · early-stage, single-arm, open-label trial; company-reported interim safety update · n = 3  ·  3 Partial reprogramming (16-day Yamanaka factor induction) in young and old mice, with multi-omics profiling  ·  4 Fight Aging! · informal/unregulated human gene therapy administration (anecdotal, unpublished)

◆◆◆◆◇  People, tested on a stand-in

Scholar Rock refiled apitegromab in Europe and a GLP-1 add-on reported a trial in one week

◆ Biomarkers are not outcomesLean mass is standing in for the strength and function outcomes the sarcopenia worry is about.

Scholar Rock resubmitted its apitegromab marketing authorisation application to the European Medicines Agency. The indication covered by that resubmission is not stated in the available reporting. It cannot be read as a filing for muscle preservation during GLP-1 therapy.

A company-reported trial says trevogrumab reduced muscle loss in patients on a GLP-1 agonist and aided muscle regain after treatment stopped. The report discloses no randomisation and no design, so the claim cannot be graded. Atrogi's 8-week, open-label, single-arm study of oral ATR-258 in 13 overweight or obese subjects is company-reported and unpublished.

Every result here measures muscle mass, not strength or function. ^5–8

HARMSNo adverse-event data accompanied the trevogrumab report. The ATR-258 study is company-reported and unpublished, so its safety data cannot be read.

WHAT WOULD MOVE THISA randomised trial in older patients reporting strength, falls or physical function.

5 clinical trial of trevogrumab added to GLP-1 therapy  ·  6 Not a study  ·  7 Longevity.Technology · open-label, single-arm, dose-escalation (3 doses), investigator-initiated · n = 13  ·  8 Revista CPAQV - Centro de Pesquisas Avançadas em Qualidade de Vida · narrative review of incretin-based obesity pharmacotherapy and body-composition/muscle outcomes

  Not a study

Nonprofit hospital systems began selling longevity packages at $5,500 to $45,000 a year

Nonprofit hospital systems are opening longevity clinics selling personalised assessments and advanced testing at $5,500 to $45,000 a year. The operator Mito sells a direct-to-consumer coronary artery calcium scan at $249 with no physician referral. Longevitix is building an AI layer meant to turn preventive-health data into continuous care.

The channel is what changed. Selling these packages inside nonprofit systems puts cash-pay testing in institutions that carry charity-care obligations. Neither the hospital clinics, nor Mito, nor Longevitix reports outcome data on buyers. ^9–11

HARMSBroad testing in people without indications produces incidental findings, and findings produce procedures. Neither the hospital clinics nor Mito reports what happened to buyers.

WHAT WOULD MOVE THISFollow-up on a cohort of package buyers: downstream procedures, findings acted on, outcomes.

9 STAT News · Not a study  ·  10–11 Longevity.Technology · Not a study

◆◆◆◆◇  People, tested on a stand-in

A skin-longevity category is forming on reviews and lab assays, with one real trial behind it

◆ Biomarkers are not outcomesSkin biomechanics and extracellular-matrix markers stand in for any health outcome; a cosmetic result is not a longevity result.

A 12-week randomised, double-blind, vehicle-controlled trial tested a topical TORC1 inhibitor against facial photoaging, measuring skin biomechanics and structural protein markers. It is a real controlled design, run against a placebo cream rather than nothing. Seven other pieces published the same week sell the same 'aging hallmark' language. They include reviews of marine collagen peptides, the skin microbiome, and skin-aging cell stress; an in vitro extract screen; a clinical framework proposal; and an opinion piece on lab-grown collagen.

None of the seven is a study of a person. The category is building commercial and scientific-sounding language around aging biology faster than it is building trial evidence for it, and the one real trial measured a cosmetic surrogate, not a health outcome. ^12–19

HARMSNo adverse-event data is reported for the trial, and the review and assay pieces carry no human safety data at all.

WHAT WOULD MOVE THISA trial that ties a skin-aging marker to a result a buyer would actually notice, or to a claim a regulator would recognise.

12 Journal of Cosmetic Dermatology · randomized, double-blind, vehicle-controlled trial, 12 weeks  ·  13 BioFactors · narrative review  ·  14 Microbiome Research Reports · narrative review  ·  15 Clinical, Cosmetic and Investigational Dermatology · conceptual review  ·  16 Longevity.Technology · Not a study  ·  17 Association for International Tea Culture · in vitro anti-aging assay study  ·  18 Skin Pharmacology and Physiology · Not a study  ·  19 Journal of Dermatology for Physician Assistants · narrative review